Related Experiment Video
Updated: Apr 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results]
Claudio Borghi1, Pasquale Perrone Filardi2
1Cattedra di Medicina Interna, Università degli Studi, Bologna.
Abstract:
The impact of low density lipoprotein (LDL) cholesterol levels on cardiovascular risk has been extensively studied. Statins have been demonstrated to significantly reduce LDL cholesterol levels, contributing to cardiovascular risk reduction particularly in patients with high cardiovascular risk. However, low adherence to statin therapy, often due to adverse effects, has raised the need for new pharmacological approaches to combine with statin therapy in order to reach the target levels of LDL cholesterol. Ezetimibe is a selective inhibitor of Niemann-Pick C1-like 1 (NPC1L1) protein that regulates the cholesterol uptake from the small intestine into the enterocytes. Ezetimibe has been demonstrated to significantly reduce LDL cholesterol levels in combination with statins and recent trials support its role in reducing the risk of cardiovascular events.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Study Design: Healthy Subjects Versus Patients
Therapeutic Drug Monitoring: Affecting Factors

